BWXT Posts 18% Revenue Growth in Q2, Raises 2026 Guidance and Sells Medical Unit for Up to $800M

BWX Technologies (NYSE: BWXT) reported Q2 2026 revenue of $901.6 million, an 18% year-over-year increase, while simultaneously announcing the sale of its medical business to Nordic Capital in a transaction valued at up to $800 million. The company also raised its full-year 2026 financial guidance across all key metrics.

Q2 2026 Results

• Revenue: $901.6 million, up 18.0% from $764.0 million in Q2 2025, with Commercial Operations growing 72% YoY to $302.5 million and Government Operations up 2% to $601.3 million.
• GAAP EPS: $0.97 diluted, up from $0.85 in Q2 2025; adjusted (non-GAAP) EPS of $1.07, up from $1.02 a year earlier.
• GAAP net income: $89.1 million, up 13.5% from $78.5 million; adjusted net income of $98.6 million, up 5.8%.
• Adjusted EBITDA: $155.5 million, up 7% from $145.9 million, driven primarily by Commercial Operations growth.
• Free cash flow: $115.0 million for the quarter, down from $126.3 million in Q2 2025, as higher capital expenditures of $41.4 million (up 26.6% from $32.7 million) partially offset operating cash flow of $156.4 million.

What Drove the Results

Revenue grew 18.0% year over year, but GAAP operating income rose only 11.4% to $114.1 million, and non-GAAP operating income grew just 4.5% to $126.6 million, reflecting margin compression at the segment and corporate levels. Government Operations operating income declined $3.7 million to $105.7 million despite a $12.3 million revenue gain, as higher positive contract adjustments in Q2 2025 and less favorable mix weighed on the current-period comparison. Unallocated corporate expense increased $2.0 million to $15.9 million. Commercial Operations partially offset these drags, with operating income of $24.3 million, up $17.5 million year over year, though increased SG&A investment to support growth limited the segment's margin expansion.

GAAP operating margin contracted 0.7 percentage points to 12.7%, while non-GAAP operating margin narrowed 1.9 percentage points to 14.0%. The GAAP-to-adjusted gap in the quarter reflects pension and other one-time items excluded from non-GAAP reporting.

Medical Business Sale and Strategic Shift

BWXT announced a definitive agreement to sell BWXT Medical and Kinectrics' stable medical isotopes business to Nordic Capital, a healthcare-focused private equity investor, in a transaction valued at up to $800 million. The divestiture is designed to sharpen BWXT's focus on nuclear national security and commercial nuclear power, the company's two core segments. BWXT noted it will retain a minority stake in the medical business following the close of the transaction. The sale follows BWXT's July 1, 2026 acquisition of Precision Components Group, LLC (PCG), which established a U.S. manufacturing footprint for commercial nuclear components and is included in the company's updated full-year guidance.

Raised 2026 Guidance

BWXT raised its full-year 2026 outlook across all metrics: revenue guidance increased to approximately $3,800 million from prior guidance of more than $3,750 million; adjusted EBITDA guidance moved to $662 million to $672 million from $650 million to $665 million; non-GAAP EPS guidance rose to $4.70 to $4.80 from $4.60 to $4.75; and free cash flow guidance was raised to $345 million to $360 million from $315 million to $330 million.

Wall Street View

Analyst sentiment heading into the report leaned constructive, with the majority of covering firms holding Buy or Strong Buy ratings as of July 2026. The raised guidance and announced divestiture give analysts concrete updated figures to model, particularly as the PCG acquisition begins contributing to results.

Investor Takeaway

The Q2 results confirm strong top-line momentum in Commercial Operations, but investors should note that revenue growth is running well ahead of operating income growth, a spread that reflects deliberate SG&A investment and the Government segment's year-over-year contract-mix headwind. The up-to-$800 million medical unit sale, if closed at the high end of its valuation range, would represent a material capital event relative to BWXT's current debt load of approximately $2.02 billion, potentially reshaping the company's balance sheet and capital allocation capacity as it doubles down on nuclear defense and power infrastructure.